Your browser is no longer supported. Please, upgrade your browser.
Supernus Pharmaceuticals, Inc.
Index- P/E11.15 EPS (ttm)2.41 Insider Own0.10% Shs Outstand52.66M Perf Week-9.25%
Market Cap1.39B Forward P/E16.72 EPS next Y1.61 Insider Trans-70.67% Shs Float50.79M Perf Month-13.10%
Income129.30M PEG6.60 EPS next Q0.52 Inst Own- Short Float14.08% Perf Quarter26.69%
Sales477.30M P/S2.92 EPS this Y2.40% Inst Trans2.71% Short Ratio12.28 Perf Half Y19.32%
Book/sh13.46 P/B2.00 EPS next Y-30.37% ROA9.70% Target Price31.00 Perf Year49.28%
Cash/sh6.79 P/C3.96 EPS next 5Y1.69% ROE20.00% 52W Range13.12 - 31.99 Perf YTD6.80%
Dividend- P/FCF9.61 EPS past 5Y58.90% ROI12.10% 52W High-16.00% Beta1.27
Dividend %- Quick Ratio1.70 Sales past 5Y33.50% Gross Margin92.00% 52W Low104.80% ATR1.43
Employees464 Current Ratio1.80 Sales Q/Q51.90% Oper. Margin35.90% RSI (14)38.75 Volatility6.38% 4.37%
OptionableYes Debt/Eq0.54 EPS Q/Q38.70% Profit Margin27.10% Rel Volume2.92 Prev Close29.45
ShortableYes LT Debt/Eq0.53 Earnings- Payout0.00% Avg Volume582.52K Price26.87
Recom2.50 SMA20-10.26% SMA50-3.24% SMA20013.23% Volume1,701,493 Change-8.76%
Jun-16-20Upgrade Piper Sandler Neutral → Overweight $25 → $31
Jun-15-20Resumed Jefferies Hold $24
Nov-08-19Downgrade Berenberg Buy → Hold
Nov-07-19Downgrade Stifel Buy → Hold $55 → $23
Nov-06-19Downgrade Jefferies Buy → Hold $46 → $23
Nov-12-18Reiterated B. Riley FBR Buy $68 → $65
Jan-18-18Reiterated B. Riley FBR, Inc. Buy $54
Dec-28-17Reiterated B. Riley FBR, Inc. Buy $50 → $54
Dec-04-17Upgrade Janney Neutral → Buy
Nov-08-17Upgrade Stifel Hold → Buy $47
Oct-19-17Initiated FBR & Co. Buy $53
Sep-19-17Downgrade Stifel Buy → Hold $47
Jul-17-17Downgrade Piper Jaffray Overweight → Neutral
Jul-14-17Initiated Janney Neutral
Jun-01-17Upgrade Piper Jaffray Neutral → Overweight
Jul-18-16Downgrade Piper Jaffray Overweight → Neutral
Jul-18-16Downgrade Northland Capital Outperform → Market Perform
Feb-08-16Upgrade Jefferies Hold → Buy
Nov-05-15Reiterated Northland Capital Outperform $26 → $27
Oct-28-15Initiated Northland Capital Outperform $26
Feb-27-21 06:15AM  
Feb-26-21 10:01AM  
Feb-25-21 04:37PM  
Feb-23-21 09:00AM  
Feb-22-21 08:00AM  
Feb-08-21 09:00AM  
Feb-04-21 04:10PM  
Feb-03-21 06:52AM  
Jan-25-21 02:20PM  
Jan-12-21 12:48PM  
Jan-06-21 05:29PM  
Dec-24-20 10:02AM  
Dec-23-20 02:28PM  
Dec-22-20 06:53PM  
Dec-07-20 10:56AM  
Nov-28-20 11:50PM  
Nov-27-20 11:00AM  
Nov-26-20 12:30AM  
Nov-23-20 10:00PM  
Nov-22-20 01:37AM  
Nov-19-20 03:30PM  
Nov-18-20 10:00PM  
Nov-16-20 11:00PM  
Nov-14-20 03:00PM  
Nov-11-20 09:45PM  
Nov-10-20 08:40AM  
Nov-09-20 06:30PM  
Nov-04-20 01:30PM  
Nov-03-20 05:45PM  
Oct-27-20 05:30PM  
Oct-13-20 01:13PM  
Oct-05-20 04:00PM  
Sep-28-20 10:01AM  
Sep-25-20 07:09AM  
Sep-24-20 07:10AM  
Sep-14-20 08:15AM  
Sep-09-20 04:30PM  
Sep-02-20 04:30PM  
Aug-19-20 12:00PM  
Aug-18-20 07:25PM  
Aug-16-20 09:12AM  
Aug-12-20 07:29AM  
Aug-11-20 04:30PM  
Aug-10-20 08:36AM  
Jul-30-20 12:10PM  
Jul-28-20 12:33PM  
Jun-26-20 06:29PM  
Jun-19-20 01:47AM  
Jun-09-20 03:46PM  
Jun-02-20 10:00AM  
May-27-20 04:30PM  
May-15-20 04:15PM  
May-09-20 04:17PM  
May-07-20 05:30PM  
May-05-20 08:25PM  
Apr-30-20 09:40AM  
Apr-29-20 08:40AM  
Apr-28-20 05:00PM  
Apr-24-20 04:30PM  
Apr-21-20 04:15PM  
Apr-15-20 11:21AM  
Mar-30-20 05:20PM  
Mar-16-20 10:34AM  
Mar-13-20 11:16AM  
Mar-09-20 01:30PM  
Feb-26-20 01:14PM  
Feb-25-20 05:55PM  
Feb-17-20 01:22PM  
Feb-11-20 04:05PM  
Jan-22-20 08:25AM  
Jan-21-20 06:33PM  
Jan-16-20 10:59AM  
Jan-08-20 10:30AM  
Dec-16-19 02:00PM  
Dec-11-19 08:52AM  
Supernus Pharmaceuticals, Inc., a pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in neurology and psychiatry in the United States. The company offers Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and in children 6 to 17 years of age; and Trokendi XR, an extended release topiramate, which is used for the prophylaxis of migraine headache, as well as for the treatment of epilepsy. Its product candidates comprise SPN-812, a viloxazine hydrochloride, which has completed phase III clinical trial that is used for the treatment of attention deficit hyperactivity disorder (ADHD); SPN-809, a viloxazine hydrochloride, which is in phase II ready clinical trial for the treatment of depression; SPN-604 extended release oxcarbazepine, which is in phase III clinical trial for the treatment of bipolar disorder; and SPN-817 that is in phase I clinical trial to treat severe pediatric epilepsy disorders. The company markets its products through pharmaceutical wholesalers and distributors. It has a development and option agreement with Navitor Pharmaceuticals, Inc. to conduct a phase II clinical program for NV-5138 in treatment-resistant depression. Supernus Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Rockville, Maryland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Schwabe Stefan K.F.Executive Vice President & CMODec 21Option Exercise12.9846,347601,58449,119Dec 22 05:49 PM
Schwabe Stefan K.F.Executive Vice President & CMODec 21Sale22.1046,3471,024,4632,772Dec 22 05:49 PM
Schwabe Stefan K.F.Executive Vice President & CMODec 14Option Exercise9.3953,653503,91656,425Dec 15 08:20 PM
Schwabe Stefan K.F.Executive Vice President & CMODec 14Sale21.8753,6531,173,2642,772Dec 15 08:20 PM
PATRICK GREGORY SSr. VP Chief Financial OfficerNov 09Option Exercise12.985,00064,90049,463Nov 10 04:19 PM
PATRICK GREGORY SSr. VP Chief Financial OfficerNov 09Sale25.005,000125,00044,463Nov 10 04:19 PM
PATRICK GREGORY SSr. VP, CFONov 05Option Exercise12.985,00064,90049,463Nov 06 05:43 PM
PATRICK GREGORY SSr. VP, CFONov 05Sale23.005,000115,00044,463Nov 06 05:43 PM
PATRICK GREGORY SSr. VP, CFOOct 15Option Exercise12.9815,000194,70059,463Oct 15 06:04 PM
PATRICK GREGORY SSr. VP, CFOOct 15Sale20.0315,000300,50744,463Oct 15 06:04 PM
Hudson Frederick M.DirectorJul 13Option Exercise2.568,75022,40018,961Jul 15 04:39 PM
Hudson Frederick M.DirectorJul 13Sale24.4492022,48518,041Jul 15 04:39 PM
PATRICK GREGORY SSr.VP, Chief Financial OfficerMay 20Option Exercise12.9815,000194,70061,057May 20 06:59 PM
PATRICK GREGORY SSr.VP, Chief Financial OfficerMay 20Sale25.0315,000375,38046,057May 20 06:59 PM
PATRICK GREGORY SSr VP, Chief Financial OfficerMay 08Option Exercise9.1315,000136,95061,057May 11 06:42 PM
PATRICK GREGORY SSr VP, Chief Financial OfficerMay 08Sale23.1415,000347,03446,057May 11 06:42 PM